Your Partner in Oncology Research

Cancer Efficacy Models

Noble Life Sciences is a full-service preclinical oncology CRO. Our trained scientists specialize in accelerating the development of new cancer immunotherapies, vaccines, and cell therapies to improve patient outcomes.

We ensure the creation of unique models for:

Over 25 years, our oncology team has performed thousands of studies

Mouse Models

  • Syngeneic Tumor Models
  • Orthotopic, Metastasis/Disseminated Xenograft Models
  • Humanized Mouse Models
  • Patient-derived Xenograft Models (PDX)
  • Cell Line-derived Xenograft Models (CDX)
    • Humanized Mouse Model for CAR-T, CAR-NK, or Other Immunotherapies
    • Metastatic Models
    • Leukemia Models
    • Cell Therapy Models
    • Breast Adenocarcinoma Model


  • IVIS Optical Live Animal Imaging
  • Fluoroscopy Imaging System
  • Radiology
  • Ultrasound


  • Expansion and Activation of CAR-T Cells
  • Proliferation, Activation, Cytolytic Activity & Cytokine Production of CAR-T Cells)


  • Flexibility to Build Out T-cell Production Capabilities
  • Flow Cytometry-Based Assays to Support Immuno-oncology Drug Development
  • Cytotoxicity and Immunotoxicity Assays
  • PK/PD and Efficacy Studies
  • Flow and PCR-based Biodistribution Assays
  • Cellular Activation and Stimulation Assays
  • Human Whole Blood Stimulation Assays

Only for conference participants
get 5% off your first study

Oncology Drug Testing  cover thumbnail

Preclinical Capabilities Sheet

Oncology Drug Testing  cover thumbnail

Oncology Drug Testing

Cell & Gene Therapy

Scientific Advisor Team

Our oncology team is committed to fight The Fight

by advancing your preclinical research.

Stephen K. Horrigan, Ph.D.

Stephen K. Horrigan, Ph.D.

Chief Scientific Officer

Pang-Kuo Lo, Ph.D. MSc

Pang-Kuo Lo, Ph.D. MSc

Team Lead, Assay Development

Arundhati Ghosh, Ph.D., MSc

Arundhati Ghosh, Ph.D., MSc

Study Director

Yongping Chen, M.D., Ph.D.

Yongping Chen, M.D., Ph.D.

Senior Study Director